Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.

Single-agent arsenic trioxide has shown promising results in patients with relapsed or refractory multiple myeloma (MM). Because preclinical data suggested greater activity with dexamethasone and ascorbic acid, a phase 2 trial of the combination of arsenic trioxide, dexamethasone, and ascorbic acid in patients with relapsed or refractory MM was conducted.
Twenty patients in whom no more than two previous therapies had failed were enrolled. The mean age was 62 yr, and 55% of the patients had refractory disease. The regimen consisted of 14- or 15-wk cycles, with the first cycle considered induction, followed by one or two consolidation cycles with a reduced steroid schedule and then a maintenance cycle in responding patients.
The overall response rate was 30%, with at least stable disease in 80% of patients. Median progression- free survival was 316 d in all patients and 584 d in those with a response. The regimen was well tolerated, with most adverse events being mild or moderate.
This study showed the clinical efficacy and tolerability of the combination of arsenic trioxide, dexamethasone, and ascorbic acid. Further study is warranted.
AuthorsRony M Abou-Jawde, Janice Reed, Megan Kelly, Esteban Walker, Steven Andresen, Rachid Baz, Mary Ann Karam, Mohamad Hussein
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 23 Issue 2 Pg. 263-72 ( 2006) ISSN: 1357-0560 [Print] United States
PMID16720927 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • Arsenicals
  • Oxides
  • Vitamins
  • Dexamethasone
  • Ascorbic Acid
  • arsenic trioxide
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
  • Arsenicals (administration & dosage, adverse effects)
  • Ascorbic Acid (administration & dosage, adverse effects)
  • Dexamethasone (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma (drug therapy, mortality)
  • Oxides (administration & dosage, adverse effects)
  • Recurrence
  • Vitamins (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: